Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of this study is to assess whether the efficacy of ocrelizumab 600 mg intravenously every 24 weeks is superior to Rebif® as measured by the annualized protocol-defined relapse rate by two years in patients with relapsing multiple sclerosis.
Inclusion criteria
- Relapsing Multiple Sclerosis